Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/02/2010WO2010093789A3 A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lh-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
12/02/2010WO2010088064A3 Preservation of ergothioneine
12/02/2010WO2010087947A3 Transdermal delivery of diclofenac, carbamazepine and benzydamine
12/02/2010WO2010083385A3 Compounds for reducing drug resistance and uses thereof
12/02/2010WO2010083384A3 Non-peptidyl, potent, and selective mu opioid receptor antagonists
12/02/2010WO2010080970A3 Oral enteric antidepressant formulation
12/02/2010WO2010059253A3 Methods and compositions for localized agent delivery
12/02/2010WO2010057028A3 Treatment of proteinopathies using a farnesyl transferase inhibitor
12/02/2010WO2010049438A3 Improved methods of using phosphoantigens for the treatment of diseases
12/02/2010WO2010049182A3 Treatment of retroviral reservoirs exploiting oxidative stress
12/02/2010WO2010043950A3 Propafenone extended release composition
12/02/2010WO2010035219A3 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
12/02/2010WO2010023422A8 Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
12/02/2010WO2010007482A3 Thiazole derivatives as stearoyl coa desaturase inhibitors
12/02/2010WO2009154304A3 A pharmaceutical composition comprising rebamipide
12/02/2010WO2009146408A9 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
12/02/2010WO2009137899A3 Sulfated galactans with antithrombotic activity, pharmaceutical composition, method for treating or prophylaxis of arterial or venous thrombosis, method of extraction and use thereof
12/02/2010WO2009124371A9 Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
12/02/2010WO2009120699A3 Antimicrobials having polyquarternary ammoniums and alcohol-bearing amidoamines and methods for their use
12/02/2010WO2009067243A8 Modulation of cd40 expression
12/02/2010US20100305522 Fluid medication delivery device
12/02/2010US20100305521 Fluid medication delivery device
12/02/2010US20100305500 Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
12/02/2010US20100305214 Use of a Monoterpene to Increase Tissue Repair
12/02/2010US20100305213 Treatment of heart disease using beta-blockers
12/02/2010US20100305212 Therapeutic compounds
12/02/2010US20100305211 Gentle-Acting Skin-Disinfectants and Hydroalcoholic Gel Formulations
12/02/2010US20100305210 S-alkylisothiouronium derivatives for treating abnormal uterine bleeding disorders
12/02/2010US20100305209 Articles of Manufacture Releasing an Active Ingredient
12/02/2010US20100305208 Gastric retention controlled drug delivery system
12/02/2010US20100305207 Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
12/02/2010US20100305206 Modulation of nitric oxide synthases by betaines
12/02/2010US20100305205 Composition and/or method for preventing recurrence of stroke
12/02/2010US20100305204 Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
12/02/2010US20100305203 Method for modulating claudin mediated functions
12/02/2010US20100305202 Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same
12/02/2010US20100305201 Method of Treating a Tumor and Biodistribution of a Drug Delivered by Worm-Like Filomicelles
12/02/2010US20100305200 Compounds that modulate intracellular calcium
12/02/2010US20100305199 Therapeutic regimen for treating cancer
12/02/2010US20100305197 Conditionally Active Ribozymes And Uses Thereof
12/02/2010US20100305196 COMPOSITION FOR TREATING PROSTATE CANCER (PCa)
12/02/2010US20100305195 microrna mediator of cardiomyopathy and heart failure
12/02/2010US20100305194 Modified and stabilized gdf propeptides and uses thereof
12/02/2010US20100305193 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
12/02/2010US20100305192 Compositions and methods for short interfering nucleic acid inhibition of nav1.8
12/02/2010US20100305191 Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering rna
12/02/2010US20100305190 Nucleic acid complex and nucleic acid delivery composition
12/02/2010US20100305189 Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
12/02/2010US20100305188 Nucleic acid capable of regulating the proliferation of cell
12/02/2010US20100305187 Methods and compounds for treating diseases caused by reactive oxygen species
12/02/2010US20100305186 Methods for mediating gene suppression
12/02/2010US20100305185 Diagnostic method
12/02/2010US20100305184 Inhibitors of the atb(0,+) transporter and uses thereof
12/02/2010US20100305183 Method and composition for reducing reperfusion injury
12/02/2010US20100305182 Compounds and methods for modulating communication and virulence in quorum sensing bacteria
12/02/2010US20100305181 Methods for treating a variety of diseases and conditions, and compounds useful therefor
12/02/2010US20100305180 Inhibitors of ubiquitin e1
12/02/2010US20100305179 Oral sustained-release tablet
12/02/2010US20100305178 Pharmaceutical Composition
12/02/2010US20100305177 Prophylactic or therapeutic agent for diabetic maculopathy
12/02/2010US20100305176 (s,r.)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
12/02/2010US20100305175 Pharmaceutical latrunculin formulations
12/02/2010US20100305174 Novel Heterocyclic Derivatives
12/02/2010US20100305173 Hydroxyethylamino sulfonamide derivatives
12/02/2010US20100305172 Methods for Concomitant Administration of Colchicine and a Second Active Agent
12/02/2010US20100305171 gout flares; ritonavir; side effect reduction of colchicine
12/02/2010US20100305167 Administration of an Inhibitor of HDAC
12/02/2010US20100305166 Novel compounds
12/02/2010US20100305165 Thiocolchicine derivatives, method of making and methods of use thereof
12/02/2010US20100305164 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
12/02/2010US20100305163 Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
12/02/2010US20100305162 Methods for the Synthesis of Pyridoxamine
12/02/2010US20100305160 Anesthetic methods and compositions
12/02/2010US20100305159 Crystalline form of piperidine compound
12/02/2010US20100305158 Method for the treatment or prevention of lower urinary tract symptoms
12/02/2010US20100305157 derivatives of dicarboxylic amino acids and their application in the treatment of neurodegenerative diseases
12/02/2010US20100305156 Inhibitors of c-met protein kinase
12/02/2010US20100305155 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010US20100305154 Prolyl Hydroxylase Inhibitors
12/02/2010US20100305153 Aminoisoquinoline thrombin inhibitor with improved bioavailability
12/02/2010US20100305151 O-Methylated Rapamycin Derivatives For Alleviation And Inhibition Of Lymphoproliferative Disorders
12/02/2010US20100305150 Tuberous sclerosis treatment
12/02/2010US20100305149 Polyal Drug Conjugates Comprising Variable Rate-Releasing Linkers
12/02/2010US20100305148 Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
12/02/2010US20100305147 Chemically modified small molecules
12/02/2010US20100305146 Method for the Production of 1,3-Dioxolane-2-Ones and Carboxylic Acid Esters by Means of Transacylation in Basic Reaction Conditions
12/02/2010US20100305145 Substituted Aminobutyric Derivatives as Neprilysin Inhibitors
12/02/2010US20100305144 Prevention of recurrence of urethral stricture after a conventional treatment
12/02/2010US20100305143 Pyrrolopyrimidine compounds
12/02/2010US20100305142 3-aminoimidazo 1,2-a pyridine derivatives having an sglt1- and sglt2-inhibiting action for the treatment of type 1 and type 2 diabetes
12/02/2010US20100305141 Tetrahydroindolone derivatives for treatment of neurological conditions
12/02/2010US20100305140 Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
12/02/2010US20100305139 Method of treating abnormal lipid metabolism
12/02/2010US20100305138 Pyridyl derivatives and their use as therapeutic agents
12/02/2010US20100305137 Piperazine derivatives and methods of use
12/02/2010US20100305136 Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
12/02/2010US20100305135 Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
12/02/2010US20100305134 Specific inhibitors of pteridine reductase with antiparasitic action
12/02/2010US20100305133 Prolyl Hydroxylase Inhibitors
12/02/2010US20100305131 Substituted Aminopropionic Derivatives as Neprilysin inhibitors
1 ... 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 ... 7860